反应详情

The title compound (0.12 g, 0.17 mmol, 67%) was prepared from 5-[3-(2-chloro-4-pyrimidinyl)imidazo[1,2-a]pyridin-2-yl]-N-(2,6-difluorophenyl)-2-(ethyloxy)benzamide (Intermediate Example 6) and 2-(methyloxy)-4-[2-(4-methyl-1-piperazinyl)ethyl]aniline (Example 131, step D) in an analogous manner to that described for Example 26, step E. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.40 (t, J=6.8 Hz, 3H), 2.10 (s, 3H), 2.28 (br. s., 4H), 2.40 (br. s., 3H), 2.49 (d, J=8.4 Hz, 3H), 2.63-2.72 (m, 2H), 3.79 (s, 3H), 4.23 (q, J=6.9 Hz, 2H), 6.57 (d, J=4.9 Hz, 1H), 6.71-6.79 (m, 1H), 6.91-6.99 (m, 2H), 7.16 (t, J=8.1 Hz, 2H), 7.23 (d, J=9.0 Hz, 1H), 7.30-7.37 (m, 1H), 7.37-7.46 (m, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.64-7.74 (m, 2H), 8.02 (s, 1H), 8.23 (d, J=5.3 Hz, 1H), 8.47 (s, 1H), 9.35 (d, J=6.8 Hz, 1H), 9.71 (s, 1H). MS (M+H, ES+) 720.